Health Catalyst (NASDAQ:HCAT) Price Target Cut to $19.00 by Analysts at Royal Bank of Canada

Health Catalyst (NASDAQ:HCATGet Rating) had its price objective decreased by equities research analysts at Royal Bank of Canada from $35.00 to $19.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Royal Bank of Canada’s price target would suggest a potential upside of 46.72% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Guggenheim assumed coverage on shares of Health Catalyst in a research report on Wednesday, April 13th. They issued a “buy” rating and a $39.00 price objective for the company. Raymond James lowered their price target on Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating for the company in a report on Friday, March 4th. Jefferies Financial Group upgraded Health Catalyst from a “hold” rating to a “buy” rating and cut their price objective for the company from $31.00 to $28.00 in a report on Thursday, March 17th. BTIG Research lowered their target price on Health Catalyst from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Friday, March 25th. Finally, Piper Sandler cut their price target on shares of Health Catalyst from $38.00 to $21.00 in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Health Catalyst has a consensus rating of “Buy” and a consensus target price of $36.23.

Shares of HCAT stock opened at $12.95 on Wednesday. The stock has a market cap of $698.48 million, a PE ratio of -4.03 and a beta of 1.18. The stock has a 50-day moving average of $22.49 and a 200-day moving average of $32.50. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.46 and a quick ratio of 5.46. Health Catalyst has a one year low of $12.53 and a one year high of $59.50.

Health Catalyst (NASDAQ:HCATGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. The firm had revenue of $68.09 million during the quarter, compared to analysts’ expectations of $66.01 million. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.37) earnings per share. As a group, research analysts anticipate that Health Catalyst will post -1.8 earnings per share for the current year.

In related news, insider Linda Llewelyn sold 2,039 shares of Health Catalyst stock in a transaction dated Tuesday, March 15th. The stock was sold at an average price of $21.08, for a total value of $42,982.12. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Daniel H. Orenstein sold 4,112 shares of the company’s stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total value of $110,283.84. The disclosure for this sale can be found here. Insiders have sold a total of 37,286 shares of company stock valued at $934,979 over the last ninety days. Company insiders own 2.00% of the company’s stock.

Several large investors have recently bought and sold shares of HCAT. CNA Financial Corp boosted its holdings in shares of Health Catalyst by 1.2% in the 3rd quarter. CNA Financial Corp now owns 21,090 shares of the company’s stock valued at $1,055,000 after buying an additional 250 shares during the last quarter. Advisor Group Holdings Inc. increased its holdings in Health Catalyst by 27.3% during the third quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after buying an additional 314 shares during the last quarter. Voya Investment Management LLC raised its position in Health Catalyst by 1.9% during the third quarter. Voya Investment Management LLC now owns 17,616 shares of the company’s stock worth $881,000 after acquiring an additional 328 shares in the last quarter. Rhumbline Advisers lifted its stake in Health Catalyst by 0.8% in the fourth quarter. Rhumbline Advisers now owns 49,095 shares of the company’s stock valued at $1,945,000 after acquiring an additional 409 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Health Catalyst by 23.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,452 shares of the company’s stock valued at $123,000 after acquiring an additional 463 shares during the period. 97.53% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

See Also

The Fly logo

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.